Małkiewicz, B.; Gurwin, A.; Karwacki, J.; Nagi, K.; Knecht-Gurwin, K.; Hober, K.; Łyko, M.; Kowalczyk, K.; Krajewski, W.; Kołodziej, A.; Szydełko, T. Management of Bladder Cancer Patients with Clinical Evidence of Lymph Node Invasion (cN+). Cancers2022, 14, 5286.
Małkiewicz, B.; Gurwin, A.; Karwacki, J.; Nagi, K.; Knecht-Gurwin, K.; Hober, K.; Łyko, M.; Kowalczyk, K.; Krajewski, W.; Kołodziej, A.; Szydełko, T. Management of Bladder Cancer Patients with Clinical Evidence of Lymph Node Invasion (cN+). Cancers 2022, 14, 5286.
Małkiewicz, B.; Gurwin, A.; Karwacki, J.; Nagi, K.; Knecht-Gurwin, K.; Hober, K.; Łyko, M.; Kowalczyk, K.; Krajewski, W.; Kołodziej, A.; Szydełko, T. Management of Bladder Cancer Patients with Clinical Evidence of Lymph Node Invasion (cN+). Cancers2022, 14, 5286.
Małkiewicz, B.; Gurwin, A.; Karwacki, J.; Nagi, K.; Knecht-Gurwin, K.; Hober, K.; Łyko, M.; Kowalczyk, K.; Krajewski, W.; Kołodziej, A.; Szydełko, T. Management of Bladder Cancer Patients with Clinical Evidence of Lymph Node Invasion (cN+). Cancers 2022, 14, 5286.
Abstract
The purpose of this review is to present the current knowledge about the diagnostic and treatment options in bladder cancer (BCa) patients with clinically positive lymph nodes (cN+). In this review compaction of CT and MRI performance in preoperative prediction of lymph node invasion (LNI) in BCa patients was presented, along with other diagnostic methods. Most scientific societies do not distinguish cN+ patients in their guidelines, recommendations concern muscle-invasive bladder cancer (MIBC) and differ between associations. Currently, the standard treatment of patients with MIBC is radical cystectomy (RC) with bilateral pelvic lymph node dis-section (PLND). The template of PLND and its therapeutic value remain debatable. Moreover, most guidelines recommend neoadjuvant chemotherapy (NAC). However, there is still lack of definitive evidence of the superiority of neoadjuvant chemotherapy over adjuvant chemotherapy. Nevertheless, the curative treatment that provides the best long-term survival in cN+ patients is a multimodal approach with a combination of chemotherapy and RC. Recent studies demonstrate the growing importance of immunotherapy. Special attention should be paid to cN+ BCa patients as the oncological outcomes are significantly worse for this group.
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.